Pallas Capital Advisors LLC

Position in ALNY — Alnylam Pharmaceuticals, Inc.

CIK 1862282 BRAINTREE, MA

Position in ALNY

as of Mar 31, 2026 · filed Apr 21, 2026 Compact

Position Value

$731,884

-$902,059 QoQ

Shares Held

2,212

-46.2% QoQ

Ownership

0.002%

of shares outstanding

% of Portfolio

0.04%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2024

8 quarters on record

Voting authority Sole 16.229656419529835.ToString("F0")% Shared 0.ToString("F0")% None 83.77034358047017.ToString("F0")%

Healthcare · as of Mar 31, 2026

Pallas Capital Advisors LLC holds $23,981,428 across 32 Biotechnology names. ALNY ranks #6 (3.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	AXSM	Axsome Therapeutics, Inc.	40,610	$6,863,902
2	RPRX	Royalty Pharma plc	102,969	$4,939,422
3	INCY	Incyte Corp	33,157	$3,120,736
4	REGN	Regeneron Pharmaceuticals, Inc.	2,680	$2,070,675
5	EXEL	Exelixis, Inc.	29,215	$1,253,031
6	ALNY	Alnylam Pharmaceuticals, Inc. This page	2,212	$731,884
7	VRTX	Vertex Pharmaceuticals Inc / Ma	1,638	$731,432
8	BMRN	Biomarin Pharmaceutical Inc	12,396	$700,250

8 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$731,884	2,212	-46.2%	Shares	Sole	2026-04-21
2025-12-31	$1,633,943	4,109	-7.1%	Shares	Sole	2026-01-14
2025-09-30	$2,017,800	4,425	+72.2%	Shares	Sole	2025-11-07
2025-06-30	$838,051	2,570	-61.3%	Shares	Sole	2025-07-09
2025-03-31	$1,791,582	6,635	+94.7%	Shares	Sole	2025-04-14
2024-12-31	$801,936	3,408	+2.6%	Shares	Sole	2025-01-13
2024-09-30	$913,374	3,321	+61.8%	Shares	Sole	2024-10-25
2024-06-30	$498,636	2,052	—	Shares	Sole	2024-07-22
No filing history on record for this holder in this stock.